Research ExplorerPublications13q deletion is linked to an adverse phenotype and poor prog...

13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer

Standard

13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer. / Kluth, Martina; Scherzai, Sekander; Büschek, Franziska; Fraune, Christoph; Möller, Katharina; Höflmayer, Doris; Minner, Sarah; Göbel, Cosima; Möller-Koop, Christina; Hinsch, Andrea; Neubauer, Emily; Tsourlakis, Maria Christina; Sauter, Guido; Heinzer, Hans; Graefen, Markus; Wilczak, Waldemar; Luebke, Andreas M; Burandt, Eike; Steurer, Stefan; Schlomm, Thorsten; Simon, Ronald.

In: GENE CHROMOSOME CANC, Vol. 57, No. 10, 10.2018, p. 504-512.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kluth, M, Scherzai, S, Büschek, F, Fraune, C, Möller, K, Höflmayer, D, Minner, S, Göbel, C, Möller-Koop, C, Hinsch, A, Neubauer, E, Tsourlakis, MC, Sauter, G, Heinzer, H, Graefen, M, Wilczak, W, Luebke, AM, Burandt, E, Steurer, S, Schlomm, T & Simon, R 2018, '13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer', GENE CHROMOSOME CANC, vol. 57, no. 10, pp. 504-512. https://doi.org/10.1002/gcc.22645

APA

Kluth, M., Scherzai, S., Büschek, F., Fraune, C., Möller, K., Höflmayer, D., Minner, S., Göbel, C., Möller-Koop, C., Hinsch, A., Neubauer, E., Tsourlakis, M. C., Sauter, G., Heinzer, H., Graefen, M., Wilczak, W., Luebke, A. M., Burandt, E., Steurer, S., ... Simon, R. (2018). 13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer. GENE CHROMOSOME CANC, 57(10), 504-512. https://doi.org/10.1002/gcc.22645

Vancouver

Kluth M, Scherzai S, Büschek F, Fraune C, Möller K, Höflmayer D et al. 13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer. GENE CHROMOSOME CANC. 2018 Oct;57(10):504-512. https://doi.org/10.1002/gcc.22645

Bibtex

@article{b456ec382b024859ae53a039959512b7,
title = "13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer",
abstract = "Deletions of chromosome arm 13q belong to the most frequent molecular alterations in prostate cancer. To better understand the role of 13q deletion in prostate cancer we took advantage of our large prostate cancer tissue microarray comprising more than 12 000 cancer samples with full pathological and clinical follow-up data. Fluorescence in situ hybridization with probes for ENOX1 (13q14.11) and the retinoblastoma gene (RB1, 13q14.2) was employed. A 13q deletion was found in 21% of 7375 analyzable cancers. Deletions were always heterozygous and associated with high Gleason grade (P < .0001), advanced tumor stage (P < .0001), high preoperative prostate-specific antigen (PSA) levels (P = .0125), lymph node metastasis (P = .0377), positive resection margin (P = .0064), and early biochemical recurrence (P < .0001). 13q deletions were marginally more frequent in prostate cancers with negative ERG status (22.9%) than in ERG-positive tumors (18.7%; P < .0001). Loss of 13q predicted patient prognosis independently from established prognostic parameters that are available at the time of biopsy (P = .0004), including preoperative PSA level, clinical tumor stage, and biopsy Gleason grade. In summary, the results of our study identify 13q deletion as a frequent event in prostate cancer, which is linked to an adverse phenotype and poor prognosis in this disease.",
keywords = "Adult, Aged, Biomarkers, Tumor, Chromosome Deletion, Chromosomes, Human, Pair 13, Gene Deletion, Humans, In Situ Hybridization, Fluorescence, Male, Middle Aged, NADH, NADPH Oxidoreductases, Neoplasm Grading, Neoplasm Recurrence, Local, Prognosis, Prostate-Specific Antigen, Prostatic Neoplasms, Retinoblastoma Protein, Tissue Array Analysis, Journal Article",
author = "Martina Kluth and Sekander Scherzai and Franziska B{\"u}schek and Christoph Fraune and Katharina M{\"o}ller and Doris H{\"o}flmayer and Sarah Minner and Cosima G{\"o}bel and Christina M{\"o}ller-Koop and Andrea Hinsch and Emily Neubauer and Tsourlakis, {Maria Christina} and Guido Sauter and Hans Heinzer and Markus Graefen and Waldemar Wilczak and Luebke, {Andreas M} and Eike Burandt and Stefan Steurer and Thorsten Schlomm and Ronald Simon",
note = "{\textcopyright} 2018 Wiley Periodicals, Inc.",
year = "2018",
month = oct,
doi = "10.1002/gcc.22645",
language = "English",
volume = "57",
pages = "504--512",
journal = "GENE CHROMOSOME CANC",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",
number = "10",

}

RIS

TY - JOUR

T1 - 13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer

AU - Kluth, Martina

AU - Scherzai, Sekander

AU - Büschek, Franziska

AU - Fraune, Christoph

AU - Möller, Katharina

AU - Höflmayer, Doris

AU - Minner, Sarah

AU - Göbel, Cosima

AU - Möller-Koop, Christina

AU - Hinsch, Andrea

AU - Neubauer, Emily

AU - Tsourlakis, Maria Christina

AU - Sauter, Guido

AU - Heinzer, Hans

AU - Graefen, Markus

AU - Wilczak, Waldemar

AU - Luebke, Andreas M

AU - Burandt, Eike

AU - Steurer, Stefan

AU - Schlomm, Thorsten

AU - Simon, Ronald

N1 - © 2018 Wiley Periodicals, Inc.

PY - 2018/10

Y1 - 2018/10

N2 - Deletions of chromosome arm 13q belong to the most frequent molecular alterations in prostate cancer. To better understand the role of 13q deletion in prostate cancer we took advantage of our large prostate cancer tissue microarray comprising more than 12 000 cancer samples with full pathological and clinical follow-up data. Fluorescence in situ hybridization with probes for ENOX1 (13q14.11) and the retinoblastoma gene (RB1, 13q14.2) was employed. A 13q deletion was found in 21% of 7375 analyzable cancers. Deletions were always heterozygous and associated with high Gleason grade (P < .0001), advanced tumor stage (P < .0001), high preoperative prostate-specific antigen (PSA) levels (P = .0125), lymph node metastasis (P = .0377), positive resection margin (P = .0064), and early biochemical recurrence (P < .0001). 13q deletions were marginally more frequent in prostate cancers with negative ERG status (22.9%) than in ERG-positive tumors (18.7%; P < .0001). Loss of 13q predicted patient prognosis independently from established prognostic parameters that are available at the time of biopsy (P = .0004), including preoperative PSA level, clinical tumor stage, and biopsy Gleason grade. In summary, the results of our study identify 13q deletion as a frequent event in prostate cancer, which is linked to an adverse phenotype and poor prognosis in this disease.

AB - Deletions of chromosome arm 13q belong to the most frequent molecular alterations in prostate cancer. To better understand the role of 13q deletion in prostate cancer we took advantage of our large prostate cancer tissue microarray comprising more than 12 000 cancer samples with full pathological and clinical follow-up data. Fluorescence in situ hybridization with probes for ENOX1 (13q14.11) and the retinoblastoma gene (RB1, 13q14.2) was employed. A 13q deletion was found in 21% of 7375 analyzable cancers. Deletions were always heterozygous and associated with high Gleason grade (P < .0001), advanced tumor stage (P < .0001), high preoperative prostate-specific antigen (PSA) levels (P = .0125), lymph node metastasis (P = .0377), positive resection margin (P = .0064), and early biochemical recurrence (P < .0001). 13q deletions were marginally more frequent in prostate cancers with negative ERG status (22.9%) than in ERG-positive tumors (18.7%; P < .0001). Loss of 13q predicted patient prognosis independently from established prognostic parameters that are available at the time of biopsy (P = .0004), including preoperative PSA level, clinical tumor stage, and biopsy Gleason grade. In summary, the results of our study identify 13q deletion as a frequent event in prostate cancer, which is linked to an adverse phenotype and poor prognosis in this disease.

KW - Adult

KW - Aged

KW - Biomarkers, Tumor

KW - Chromosome Deletion

KW - Chromosomes, Human, Pair 13

KW - Gene Deletion

KW - Humans

KW - In Situ Hybridization, Fluorescence

KW - Male

KW - Middle Aged

KW - NADH, NADPH Oxidoreductases

KW - Neoplasm Grading

KW - Neoplasm Recurrence, Local

KW - Prognosis

KW - Prostate-Specific Antigen

KW - Prostatic Neoplasms

KW - Retinoblastoma Protein

KW - Tissue Array Analysis

KW - Journal Article

U2 - 10.1002/gcc.22645

DO - 10.1002/gcc.22645

M3 - SCORING: Journal article

C2 - 29923647

VL - 57

SP - 504

EP - 512

JO - GENE CHROMOSOME CANC

JF - GENE CHROMOSOME CANC

SN - 1045-2257

IS - 10

ER -